. Hodgkin-'s-lymphoma-in-france, E. Chow, S. Puumala, and B. Mueller, National Registry of Childhood Leukaemia and Lymphoma, 1990-1999 Childhood cancer in relation to parental race and ethnicity: a 5-state pooled analysis, Eur J Cancer Prev Cancer, vol.13116, issue.2, pp.97-1033045, 2004.

J. Bennett, D. Catovsky, and M. Daniel, Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group, British Journal of Haematology, vol.1, issue.4, pp.451-459, 1976.
DOI : 10.1111/j.1365-2141.1976.tb03563.x

M. Bene, G. Castoldi, and W. Knapp, Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL), Leukemia, vol.9, pp.1783-1789, 1995.

M. Smith, A. Bleyer, and W. Crist, Uniform criteria for childhood acute lymphoblastic leukemia risk classification., Journal of Clinical Oncology, vol.14, issue.2, pp.680-681, 1996.
DOI : 10.1200/JCO.1996.14.2.680

M. Sullivan, T. Chen, and P. Dyment, Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphoblastic leukemia: a pediatric oncology group study, Blood, vol.60, pp.948-58, 1982.

G. Henze, R. Fengler, and . Reitera, Impact of Early Intensive Reinduction Therapy on Event-Free Survival in Children with Low-Risk Acute Lymphoblastic Leukemia, Haematol Blood Transfus, vol.33, pp.483-491, 1990.
DOI : 10.1007/978-3-642-74643-7_87

A. Reiter, M. Schrappe, and W. Ludwig, Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86, Blood, vol.84, pp.3122-3155, 1994.

H. Cavé, J. Van-der-werff-ten-bosch, and S. Sucio, Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia, New England Journal of Medicine, vol.339, issue.9, pp.591-599, 1998.
DOI : 10.1056/NEJM199808273390904

L. Norton and R. Simon, The Norton-Simon hypothesis revisited, Cancer Treat Rep, vol.70, pp.163-172, 1986.

M. Yamada, R. Wasserman, and B. Lange, Minimal Residual Disease in Childhood B-Lineage Lymphoblastic Leukemia, New England Journal of Medicine, vol.323, issue.7, pp.448-55, 1990.
DOI : 10.1056/NEJM199008163230705

J. Burchenal, M. Murphy, and R. Ellison, Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases, Blood, vol.8, pp.965-99, 1953.

N. Jourdil, X. Fonrose, and R. Boulieu, Suivi th??rapeutique pharmacologique des 6-thioguanine nucl??otides dans les maladies inflammatoires cryptog??niques de l???intestin : int??r??t et limites, Th??rapie, vol.65, issue.3, pp.177-86, 2010.
DOI : 10.2515/therapie/2010030

G. Elion, The purine path to chemotherapy, Science, vol.244, issue.4900, pp.41-47, 1989.
DOI : 10.1126/science.2649979

B. Tay, R. Lilley, and A. Murray, Inhibition of phosphoribosyl pyrophosphate amidotransferase from Ehrlich ascites-tumour cells by thiopurine nucleotides, Biochemical Pharmacology, vol.18, issue.4
DOI : 10.1016/0006-2952(69)90069-0

L. Derijks, L. Gilissen, and L. Engels, Pharmacokinetics of 6-Mercaptopurine in Patients with Inflammatory Bowel Disease, Therapeutic Drug Monitoring, vol.26, issue.3, pp.311-319, 2004.
DOI : 10.1097/00007691-200406000-00016

L. Lennard, J. Van-loon, and J. Lilleyman, Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations, Clinical Pharmacology and Therapeutics, vol.41, issue.1, pp.18-25, 1987.
DOI : 10.1038/clpt.1987.4

L. Lennard, J. Lilleyman, and J. Van-loon, Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia, The Lancet, vol.336, issue.8709, pp.225-234, 1990.
DOI : 10.1016/0140-6736(90)91745-V

K. Schmiegelow, E. Forestier, and J. Kristinsson, Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study, Leukemia, vol.39, issue.3, pp.557-64, 2009.
DOI : 10.1111/j.1365-2036.2005.02630.x

M. Relling, M. Hancock, and J. Boyett, Prognostic importance of 6- mercaptopurine dose intensity in acute lymphoblastic leukemia, Blood, vol.93, pp.2817-2840, 1999.

G. Stocco, M. Cheok, and K. Crews, Genetic Polymorphism of Inosine Triphosphate Pyrophosphatase Is a Determinant of Mercaptopurine Metabolism and Toxicity During Treatment for Acute Lymphoblastic Leukemia, Clinical Pharmacology & Therapeutics, vol.126, issue.2, pp.164-72, 2009.
DOI : 10.1016/0378-4347(87)80340-7

L. Lennard, J. Van-loon, and R. Weinshilboum, Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism, Clinical Pharmacology and Therapeutics, vol.46, issue.2, pp.149-54, 1989.
DOI : 10.1038/clpt.1989.119

A. Black, H. Mcleod, and H. Capell, Thiopurine Methyltransferase Genotype Predicts Therapy-Limiting Severe Toxicity from Azathioprine, Annals of Internal Medicine, vol.129, issue.9, pp.716-724, 1998.
DOI : 10.7326/0003-4819-129-9-199811010-00007

M. Relling, M. Hancock, and G. Rivera, Mercaptopurine Therapy Intolerance and Heterozygosity at the Thiopurine S-Methyltransferase Gene Locus, JNCI Journal of the National Cancer Institute, vol.91, issue.23, pp.2001-2009, 1999.
DOI : 10.1093/jnci/91.23.2001

G. Gupta, E. Lautenbach, and J. Lewis, Incidence and Risk Factors for Herpes Zoster Among Patients With Inflammatory Bowel Disease, Clinical Gastroenterology and Hepatology, vol.4, issue.12, pp.1483-90, 2006.
DOI : 10.1016/j.cgh.2006.09.019

U. Nygaard, N. Toft, and K. Schmiegelow, Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity*1, Clinical Pharmacology & Therapeutics, vol.75, issue.4, pp.274-81, 2004.
DOI : 10.1016/j.clpt.2003.12.001

M. Dubinsky, S. Lamothe, and H. Yang, Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease, Gastroenterology, vol.118, issue.4, pp.705-718, 2000.
DOI : 10.1016/S0016-5085(00)70140-5

T. Adam-de-beaumais, M. Fakhoury, and Y. Medard, Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy, British Journal of Clinical Pharmacology, vol.66, issue.4, pp.575-84, 2011.
DOI : 10.1111/j.1365-2125.2010.03867.x

K. Schmiegelow and M. Pulczynska, Prognostic significance of hepatotoxicity during maintenance chemotherapy for childhood acute lymphoblastic leukaemia, British Journal of Cancer, vol.61, issue.5, pp.767-72, 1990.
DOI : 10.1038/bjc.1990.172

V. Caruso, L. Iacoviello, D. Castelnuovo, and A. , Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients, Blood, vol.108, issue.7, pp.2216-2238, 2006.
DOI : 10.1182/blood-2006-04-015511

J. Piest, N. Ramsay, and A. Bennett, The effect of l-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia, The Journal of Pediatrics, vol.100, issue.6, pp.990-995, 1982.
DOI : 10.1016/S0022-3476(82)80536-2

T. Abshire, S. Gold, and L. Odom, The coagulopathy of childhood leukemia thrombin activation or primary fibrinolysis?, Cancer, vol.66, issue.4, pp.716-737, 1990.
DOI : 10.1002/1097-0142(19900815)66:4<716::AID-CNCR2820660420>3.0.CO;2-B

L. Mitchell, J. Halton, and P. Vegh, Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia, Am J Pediatr Hematol Oncol, vol.16, pp.120-126, 1994.

A. Oner, A. Gürgey, and S. Kirazi, Changes of Hemostatic Factors in Children with Acute Lymphoblastic Leukemia Receiving Combined Chemotherapy Including High Dose Methylprednisolone and L-Asparaginase, Leukemia & Lymphoma, vol.101, issue.3-4, pp.361-365, 1999.
DOI : 10.1111/j.1600-0609.1990.tb00421.x

P. Schneider, P. Van-dreden, and A. Rousseau, Increased levels of tissue factor activity and procoagulant phospholipids during treatment of children with acute lymphoblastic leukaemia, British Journal of Haematology, vol.115, issue.Suppl. 2, pp.582-92, 2010.
DOI : 10.1111/j.1365-2141.2009.07958.x

H. Muller and J. Boos, Use of ?-asparaginase in childhood ALL, Critical Reviews in Oncology/Hematology, vol.28, issue.2, pp.97-113, 1998.
DOI : 10.1016/S1040-8428(98)00015-8

L. Mitchell, H. Hoogendoorn, and P. Giles, Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L-asparaginase-induced antithrombin III deficiency, Blood, vol.83, pp.386-91, 1994.

N. Ueda, Effect of Corticosteroids on Some Hemostatic Parameters in Children with Minimal Change Nephrotic Syndrome, Nephron, vol.56, issue.4, pp.374-382, 1990.
DOI : 10.1159/000186178

K. Jørgenson, P. Sørenson, and L. Freund, Effect of Glucocorticosteroids on Some Coagulation Tests, Acta Haematologica, vol.68, issue.1, pp.39-42, 1982.
DOI : 10.1159/000206946

U. Nowak-göttl, A. Heinecke, V. Kies, and R. , Thrombotic Events Revisited in Children with Acute Lymphoblastic Leukemia, Thrombosis Research, vol.103, issue.3, pp.165-72, 2001.
DOI : 10.1016/S0049-3848(01)00286-9

V. Mall, K. Thomas, and S. Sauter, Effect of glucocorticoids, E. coli-and Erwinia Lasparaginase on hemostatic proteins in children with acute lymphoblastic leukemia

M. Totan, A. Dagdemir, and D. Albayrak, Effects of high-dose methotrexate on the hemostatic system in childhood acute lymphoblastic leukemia, Medical and Pediatric Oncology, vol.35, issue.4, pp.429-462, 2001.
DOI : 10.1002/mpo.1106

P. Knöbl and K. Lechner, 2 Acquired factor V inhibitors, Bailli??re's Clinical Haematology, vol.11, issue.2, pp.305-323, 1998.
DOI : 10.1016/S0950-3536(98)80050-4

M. Streiff and P. Ness, Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure, Transfusion, vol.7, issue.1, pp.18-26, 2002.
DOI : 10.1046/j.1537-2995.1995.35996029166.x

T. Lisman, F. Leebeek, D. Groot, and P. , Haemostatic abnormalities in patients with liver disease, Journal of Hepatology, vol.37, issue.2, pp.280-287, 2002.
DOI : 10.1016/S0168-8278(02)00199-X

P. Hoeger, K. Helmke, and K. Winkler, Chronic consumption coagulopathy due to an occult splenic haemangioma: Kasabach-Merritt syndrome, European Journal of Pediatrics, vol.125, issue.5, pp.365-373, 1995.
DOI : 10.1007/BF02072104

C. Naranjo, U. Busto, and E. Sellers, A method for estimating the probability of adverse drug reactions, Clinical Pharmacology and Therapeutics, vol.30, issue.2, pp.239-284, 1981.
DOI : 10.1038/clpt.1981.154

B. Bégaud, J. Evreux, and J. Jouglard, Imputabilité des effets inattendus ou toxiques des médicaments Actualisation de la méthode utilisée en France, Thérapie, vol.40, pp.111-119, 1985.

C. Vignand, G. Couillault, and G. Jolimoy, Decreased Activity of Clotting Factor V During ALL Consolidation Treatment with Mercaptopurine in a Child, Annals of Pharmacotherapy, vol.40, issue.10, pp.1887-1895, 2006.
DOI : 10.1345/aph.1H013

S. Poupeney, X. Dray, and S. Reignier, Decrease in factor V activity: A new adverse effect of purine analogs in inflammatory bowel diseases?, Inflammatory Bowel Diseases, vol.14, issue.7, pp.1024-1029, 2008.
DOI : 10.1002/ibd.20411

M. Aricò, G. Gamba, and E. Raiteri, Clotting abnormalities in children during maintenance chemotherapy for acute lymphoblastic leukemia, Haematologica, vol.76, pp.472-476, 1991.

A. Pereira, F. Cervantes, and J. Ribeira, Changes in the ratio of coagulation factors as the only manifestation of hepatic toxicity caused by 6-mercaptopurine], Sangre, vol.30, pp.927-958, 1985.

R. Hyslop and I. Jardine, Metabolism of 6-Thiopurines. I. Irreversible binding of a metabolite of 6-thiopurine to mammalian hepatic protein in vitro, J Pharmacol Exp Ther, vol.218, pp.621-629, 1981.

R. Hyslop and I. Jardine, Metabolism of 6-Thiopurines. II. Covalent binding of a 6- thiopurine metabolite to mammalian tissue protein in vivo, J Pharmacol Exp Ther, vol.218, pp.629-664, 1981.

C. Volonté and L. Greene, Induction of ornithine decarboxylase by nerve growth factor in PC12 cells: dissection by purine analogues, J Biol Chem, vol.265, pp.11050-11055, 1990.

C. Volonté, A. Ross, and L. Greene, Association of a purine-analogue-sensitive protein kinase activity with p75 nerve growth factor receptors., Molecular Biology of the Cell, vol.4, issue.1, pp.71-79, 1993.
DOI : 10.1091/mbc.4.1.71

K. Senali-abayratna-wansa, J. Harris, and G. Yan, The AF-1 Domain of the Orphan Nuclear Receptor NOR-1 Mediates Trans-activation, Coactivator Recruitment, and Activation by the Purine Anti-metabolite 6-Mercaptopurine, Journal of Biological Chemistry, vol.278, issue.27, pp.24776-90, 2003.
DOI : 10.1074/jbc.M300088200

K. Mann and M. Kalafatis, Factor V: a combination of Dr Jekyll and Mr Hyde, Blood, vol.101, issue.1, pp.20-30, 2003.
DOI : 10.1182/blood-2002-01-0290

D. Pittman, K. Tomkinson, and D. Michnick, Posttranslational Sulfation of Factor V Is Required for Efficient Thrombin Cleavage and Activation and for Full Procoagulant Activity, Biochemistry, vol.33, issue.22, pp.6952-6961, 1994.
DOI : 10.1021/bi00188a026

D. Pittman, K. Tomkinson, and R. Kaufman, Posttranslational requirement for functional factor V and factor VIII secretion in mammalian cells, J Biol Chem, vol.269, pp.17329-17366, 1994.

M. Kalafatis, M. Rand, and R. Jenny, Phosphorylation of factor Va and factor VIIIa by activated platelets, Blood, vol.81, pp.704-723, 1993.

J. Lipsky, Mechanism of the inhibition of the gamma-carboxylation of glutamic acid by N-methylthiotetrazole-containing antibiotics., Proceedings of the National Academy of Sciences, vol.81, issue.9, pp.2893-2897, 1984.
DOI : 10.1073/pnas.81.9.2893

T. Wood, K. Jonhson, and S. Naylor, Cefazolin Administration and 2-Methyl-1,3,4-Thiadiazole-5-Thiol in Human Tissue: Possible Relationship to Hypoprothrombinemia, Drug Metabolism and Disposition, vol.30, issue.10
DOI : 10.1124/dmd.30.10.1123